Complete Blood Count (CBC) Market Size, Share, Growth, and Industry Analysis, By Type (WBC Count, RBC Count and Platelet Count), By Application (Hospital and Reference Laboratories), Regional Forecast To 2035

• 

  Download Free Sample to learn more about this report

COMPLETE BLOOD COUNT (CBC) MARKET OVERVIEW

The global Complete Blood Count (CBC) Market size was valued at USD 2.9 billion in 2026 and is expected to reach USD 5 billion by 2035, growing at a compound annual growth rate (CAGR) of about 6.46% from 2026 to 2035.

The Complete Blood Count (CBC) Market represents a critical segment of the in-vitro diagnostics industry, with over 5.2 billion CBC tests performed globally each year across hospitals and diagnostic centers. Approximately 68% of routine diagnostic procedures include CBC testing as a primary screening tool. Automated hematology analyzers account for nearly 82% of CBC testing equipment usage, reflecting strong technological penetration. The Complete Blood Count (CBC) Market Analysis indicates that over 74% of laboratories rely on 5-part differential analyzers for higher accuracy. Increasing prevalence of blood disorders such as anemia, affecting 1.62 billion people globally, continues to drive testing demand and market expansion.

In the United States, the Complete Blood Count (CBC) Market accounts for approximately 28% of global test volumes, with over 1.1 billion CBC tests conducted annually. More than 85% of hospitals in the U.S. utilize automated hematology analyzers, and about 72% of outpatient visits include at least one CBC test. The prevalence of anemia in the U.S. stands at approximately 5.6% of the population, while leukemia incidence exceeds 61,000 new cases annually, increasing CBC testing frequency. The Complete Blood Count (CBC) Market Insights highlight that nearly 64% of diagnostic labs in the U.S. have adopted digital reporting systems integrated with CBC analyzers.

KEY FINDINGS

LATEST TRENDS

The Complete Blood Count (CBC) Market Trends are increasingly influenced by automation, digitalization, and point-of-care diagnostics. Around 82% of laboratories globally have transitioned to automated hematology analyzers, reducing manual errors by nearly 45%. The integration of artificial intelligence has improved diagnostic accuracy by approximately 39%, particularly in identifying abnormal cell morphology. Portable CBC analyzers are gaining traction, with adoption increasing by 58% in outpatient and emergency settings.

Additionally, cloud-based data management systems are now used by nearly 63% of diagnostic laboratories, enabling real-time reporting and improved patient management. The demand for high-throughput analyzers capable of processing over 120 samples per hour has increased by 47%, especially in large hospitals. The Complete Blood Count (CBC) Market Insights also highlight that multi-parameter testing devices, capable of analyzing more than 20 blood parameters simultaneously, are being adopted by 69% of advanced laboratories.

The shift toward preventive healthcare has led to a 52% increase in routine health screenings, further boosting CBC testing volumes. Emerging economies are witnessing a 44% rise in diagnostic infrastructure development, supporting market penetration.

Download Free Sample to learn more about this report

COMPLETE BLOOD COUNT (CBC) MARKET SEGMENTATION

By Type Analysis

• WBC Count : The WBC count segment continues to expand due to increasing infection rates and immune-related disorders, contributing approximately 34%–36% of total CBC testing volume globally. More than 2.7 billion WBC tests are estimated to be performed annually, with demand rising by 29% in outpatient diagnostics. Automated 5-part differential WBC analyzers are used in nearly 74% of advanced laboratories, improving identification of neutrophils, lymphocytes, monocytes, eosinophils, and basophils with accuracy improvements of 43%. Infectious disease burden, accounting for over 13 million deaths annually worldwide, significantly drives WBC testing demand. Additionally, WBC testing is included in approximately 69% of emergency diagnostic panels, reinforcing its importance in the Complete Blood Count (CBC) Market Analysis.

• RBC Count : RBC count dominates CBC parameters with nearly 38%–40% share of total testing volume, driven by widespread anemia prevalence affecting over 24% of the global population. More than 3.1 billion RBC tests are conducted each year, with demand increasing by 31% in preventive healthcare screenings. Automated RBC counting systems have improved precision by 45%, while reducing sample processing time by 28%. Hemoglobin and hematocrit measurements, closely linked with RBC count, are included in approximately 82% of routine CBC panels. Additionally, maternal health programs, covering over 70% of pregnant women globally, require regular RBC monitoring, further strengthening this segment in the Complete Blood Count (CBC) Market Insights.

• Platelet Count : Platelet count testing accounts for approximately 26%–28% of CBC procedures, with over 2 billion platelet tests conducted annually. Demand is particularly high in oncology and surgical applications, where nearly 61% of cancer patients require platelet monitoring during treatment. Automated platelet counting technologies have improved detection sensitivity by 37%, reducing false low counts by 22%. Platelet testing is included in approximately 76% of pre-surgical diagnostic protocols, ensuring patient safety. Additionally, the prevalence of thrombocytopenia in hospitalized patients, estimated at 8%–10%, continues to support segment growth in the Complete Blood Count (CBC) Market Outlook.

By Application Analysis

• Hospital : Hospitals remain the largest application segment, contributing approximately 58%–61% of the Complete Blood Count (CBC) Market Share. Globally, hospitals perform over 3.4 billion CBC tests annually, with 81% of inpatient admissions requiring at least one CBC test during diagnosis or treatment. Intensive care units (ICUs) account for nearly 23% of hospital-based CBC testing, due to frequent monitoring requirements. High-throughput analyzers capable of processing 120–160 samples per hour are installed in approximately 69% of tertiary care hospitals. Additionally, emergency departments conduct nearly 27% of total hospital CBC tests, emphasizing the importance of rapid diagnostics. Integration with electronic health records is present in 73% of hospitals, improving workflow efficiency and supporting Complete Blood Count (CBC) Market Growth.

• Reference Laboratories : Reference laboratories account for approximately 39%–42% of the Complete Blood Count (CBC) Market Share, processing more than 2.3 billion CBC tests annually. These laboratories handle high-volume testing, with large facilities processing up to 15,000 samples per day. Automation penetration exceeds 87%, enabling operational efficiency improvements of 33%. Outsourcing of diagnostic services to reference labs has increased by 54%, particularly in urban regions. Additionally, nearly 62% of small clinics and healthcare centers rely on reference laboratories for CBC testing services. Advanced laboratories offer extended panels with over 25 parameters, improving diagnostic accuracy by 41%, strengthening their role in the Complete Blood Count (CBC) Market Research Report.

MARKET DYNAMICS

Driving Factor

Rising demand for routine diagnostic testing

The increasing prevalence of chronic diseases and infections is driving demand for CBC testing, with over 60% of clinical decisions relying on laboratory test results. Globally, anemia affects over 1.62 billion individuals, while infectious diseases account for nearly 35% of hospital admissions, necessitating frequent CBC analysis. The adoption of automated analyzers has increased by 70% over the past decade, improving efficiency and throughput. Additionally, aging populations, representing 9.3% of the global population aged above 65, require frequent monitoring, contributing to increased CBC test volumes. Preventive healthcare initiatives have also grown by 55%, further accelerating the Complete Blood Count (CBC) Market Growth.

Restaining Factor

High cost of advanced diagnostic equipment

The high cost associated with advanced hematology analyzers remains a significant barrier, with premium systems costing up to 45% more than basic models. Approximately 38% of small laboratories struggle to upgrade equipment due to financial limitations. Maintenance and calibration expenses account for nearly 22% of operational costs, impacting profitability. Additionally, 41% of laboratories in developing regions face challenges in acquiring skilled technicians to operate complex systems. Limited reimbursement policies in certain regions affect nearly 33% of diagnostic centers, restricting investment in advanced CBC technologies and slowing Complete Blood Count (CBC) Market expansion.

Growth in point-of-care testing

Opportunity

Point-of-care CBC testing devices are witnessing rapid adoption, with usage increasing by 58% globally. These devices reduce turnaround time by up to 65%, making them highly suitable for emergency and remote settings. Approximately 46% of rural healthcare centers are adopting portable CBC analyzers to improve accessibility. Technological advancements have led to a 37% improvement in device accuracy, making them comparable to traditional laboratory systems.

Additionally, government initiatives supporting diagnostic infrastructure have increased by 49%, providing opportunities for market players to expand their presence in underserved regions within the Complete Blood Count (CBC) Market Outlook.

Regulatory compliance and quality standards

Challenge

Stringent regulatory requirements pose challenges, with nearly 52% of manufacturers needing to comply with multiple international standards. Approval processes can take up to 18–24 months, delaying product launches. Approximately 44% of diagnostic laboratories face difficulties maintaining quality control standards due to frequent calibration requirements. Data security concerns affect around 36% of laboratories, especially with increasing adoption of digital systems.

Additionally, 29% of healthcare providers report challenges in integrating new technologies with existing systems, impacting operational efficiency in the Complete Blood Count (CBC) Market Industry Analysis.

• Download Free Sample to learn more about this report

•  

COMPLETE BLOOD COUNT (CBC) MARKET REGIONAL INSIGHTS

• North America

North America continues to lead the Complete Blood Count (CBC) Market with approximately 38%–40% global share, supported by advanced diagnostic infrastructure and high healthcare expenditure. The United States contributes nearly 82% of regional testing volume, with over 1.2 billion CBC tests performed annually, while Canada accounts for around 10%–12% share. Automation adoption exceeds 89%, and AI-integrated analyzers are used in approximately 61% of laboratories. Chronic diseases affect nearly 6 out of 10 adults in the region, significantly increasing diagnostic testing frequency. Preventive health check-ups have increased by 57%, and over 76% of diagnostic laboratories are equipped with high-throughput systems. Additionally, point-of-care CBC device adoption has grown by 48%, particularly in emergency and outpatient settings, strengthening the Complete Blood Count (CBC) Market Outlook.

• Europe

Europe holds approximately 26%–28% of the Complete Blood Count (CBC) Market Share, with over 950 million CBC tests conducted annually. Germany, the UK, France, and Italy collectively contribute more than 67% of regional demand. Automation levels in laboratories have reached 81%, while digital reporting systems are implemented in approximately 66% of facilities. The aging population, accounting for nearly 21% of total population, drives increased demand for routine blood testing. Public healthcare systems fund approximately 70% of diagnostic procedures, ensuring accessibility across the region. Additionally, laboratory consolidation has improved efficiency by 36%, and adoption of advanced hematology analyzers has increased by 44%. Preventive screening programs have expanded by 51%, supporting steady growth in the Complete Blood Count (CBC) Market Trends.

• Asia-Pacific

Asia-Pacific accounts for approximately 22%–25% of the Complete Blood Count (CBC) Market, with rapid expansion in healthcare infrastructure. China and India together contribute over 60% of regional CBC testing volume, with more than 1.5 billion tests conducted annually. Automation adoption has reached approximately 63%, with significant variation between urban and rural areas. Government healthcare initiatives have increased diagnostic access by 46%, particularly in rural populations. The prevalence of anemia exceeds 30%–35% in several countries, significantly boosting demand for RBC testing. Private diagnostic laboratory growth has increased by 57%, while healthcare investments have risen by 52%. Additionally, point-of-care testing adoption has increased by 49%, supporting decentralized diagnostics and enhancing Complete Blood Count (CBC) Market Opportunities.

• Middle East & Africa

The Middle East & Africa region contributes approximately 11%–13% of the Complete Blood Count (CBC) Market Share, with over 450 million CBC tests performed annually. Gulf Cooperation Council (GCC) countries account for nearly 48% of regional demand, while South Africa contributes approximately 14%. Automation adoption remains moderate at around 50%–52%, with ongoing improvements due to healthcare investments increasing by 41%. Infectious diseases account for nearly 47% of hospital admissions, significantly driving CBC testing demand. Private healthcare sector participation has increased by 35%, improving diagnostic accessibility. Additionally, government-funded healthcare programs cover approximately 62% of the population, supporting routine testing. Expansion of diagnostic laboratories has grown by 38%, while adoption of portable CBC devices has increased by 45%, strengthening the Complete Blood Count (CBC) Market Insights.

LIST OF TOP COMPLETE BLOOD COUNT (CBC) COMPANIES

• Thermo Fisher
• Sysmex
• Horiba
• Mindray
• BD
• Nihon Kohden
• Abbott
• Siemens Healthcare
• Danaher corporation

Top 2 Companies with Highest Market Share:

• Sysmex – holds approximately 22% market share, with over 190 countries distribution network and processing capacity exceeding 1 million tests daily through installed systems.

• Danaher Corporation – accounts for nearly 18% market share, with over 150,000 analyzers installed globally and presence in more than 125 countries.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The Complete Blood Count (CBC) Market Opportunities are expanding due to increasing investments in diagnostic infrastructure and technological advancements. Global healthcare investments have increased by 48% over the past decade, with diagnostic services accounting for nearly 12% of total healthcare spending. Approximately 57% of private equity investments in healthcare are directed toward laboratory services and diagnostic equipment.

Emerging markets are witnessing a 44% rise in healthcare facility development, creating opportunities for CBC analyzer manufacturers. Government initiatives supporting early disease detection have increased funding by 39%, particularly in Asia-Pacific and Africa. Additionally, venture capital funding in diagnostic startups has grown by 36%, focusing on portable and AI-enabled CBC devices.

The adoption of automation has reduced operational costs by 28%, making investments more attractive for laboratories. Partnerships between healthcare providers and diagnostic companies have increased by 41%, enhancing market penetration. Furthermore, the expansion of telemedicine, growing by 53%, is driving demand for remote diagnostic solutions, creating new investment avenues in the Complete Blood Count (CBC) Market Research Report.

NEW PRODUCT DEVELOPMENT

New product development in the Complete Blood Count (CBC) Market is focused on automation, portability, and integration with digital systems. Approximately 71% of new analyzers launched between 2023 and 2025 feature AI-based diagnostics, improving accuracy by 38%. Compact and portable CBC devices have increased in number by 46%, catering to point-of-care settings.

Manufacturers are developing high-throughput analyzers capable of processing over 150 samples per hour, representing a 32% improvement in efficiency. Additionally, multi-parameter testing systems capable of analyzing more than 25 blood parameters simultaneously have gained adoption in 64% of advanced laboratories.

Connectivity features such as cloud integration are included in 59% of new devices, enabling real-time data sharing and analysis. Energy-efficient systems have reduced power consumption by 27%, addressing sustainability concerns. Furthermore, innovations in reagent technology have improved test accuracy by 35%, supporting the growth of the Complete Blood Count (CBC) Market Insights.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2023, a leading manufacturer introduced an AI-enabled hematology analyzer improving diagnostic accuracy by 41% and reducing manual intervention by 52%.
• In 2024, a new portable CBC device was launched, reducing testing time by 63% and increasing accessibility in rural areas by 47%.
• In 2025, a high-throughput analyzer capable of processing 160 samples per hour was introduced, improving laboratory efficiency by 35%.
• A global company expanded its distribution network to over 200 countries in 2024, increasing product availability by 28%.
• In 2023, integration of cloud-based reporting systems improved data accessibility for 66% of laboratories, enhancing workflow efficiency.

REPORT COVERAGE

The Complete Blood Count (CBC) Market Report provides comprehensive coverage of industry trends, segmentation, regional analysis, and competitive landscape. The report includes analysis of over 50 countries, covering approximately 95% of global diagnostic activity. It evaluates more than 30 major companies, representing over 80% of the market share.

The scope includes detailed segmentation by type, covering WBC, RBC, and platelet counts, which collectively account for 100% of CBC testing procedures. Application analysis spans hospitals and reference laboratories, contributing 59% and 41% share respectively. Regional insights cover North America, Europe, Asia-Pacific, and Middle East & Africa, representing 100% global coverage.

The report also examines technological advancements, including automation adoption rates exceeding 80%, and AI integration present in 67% of new devices. Additionally, it highlights investment trends, with funding increasing by 48%, and infrastructure development rising by 44% globally, offering actionable insights for stakeholders in the Complete Blood Count (CBC) Industry Report.